Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 5, 2002, Pages 1225-1233

  Huang, Eugene ^a   McNeese, Marsha D ^a   Strom, Eric A ^a   Perkins, George H ^a   Katz, Angela ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a   Kuerer, Henry M ^a   Singletary, S Eva ^a   Hunt, Kelly K ^a   Buzdar, Aman U ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Inoperable disease; Preoperative radiotherapy

Indexed keywords

DISEASES; PATIENT MONITORING; RADIATION; TUMORS;

MASTECTOMY;

CHEMOTHERAPY;

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; VINBLASTINE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL RECORD; MORBIDITY; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; REOPERATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036680142     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02878-X     Document Type: Article

References (35)

1. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
2. Two years of high dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas
3. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer
4. Multimodal therapy for locally advanced breast cancer
5. Pathological assessment of response to induction chemotherapy in breast cancer
6. The management of locally advanced breast cancer: A combined modality approach
7. Combined modality approach for high-risk breast cancer
8. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B study
9. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy
10. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy
11. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer
12. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer
13. Breast tumor response to primary chemotherapy predicts local and distant control as well as survival
14. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer
15. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm
16. Multinodal treatment of locoregionally advanced breast cancer
17. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer
18. Influence of the response rate obtained by neoadjuvant chemotherapy on the survival of patients with locally advanced breast cancer
19. Breast cancer
20. Combined modality treatment of stage III and inflammatory breast cancer: M. D. Anderson Cancer Center experience
21. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
22. Nonparametric estimation from incomplete observations
23. Design and analysis of randomized clinical trials requiring prolonged observation of each patient
24. Stage III and localized stage IV breast cancer: Irradiation alone vs irradiation plus surgery
25. The role of radiotherapy in the management of operable locally advanced breast cancer
26. The effect of systemic therapy on local-regional control in locally advanced breast cancer
27. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma
28. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer
29. Multidisciplinary therapy for locally advanced breast cancer: An update
30. Prognostic factors in locally advanced non-inflammatory breast cancer: Long term results following primary chemotherapy
31. Results of a conservative treatment combining induction and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer IIIA-IIIB
32. Six-year results of a multimodality treatment strategy for local advanced breast cancer
33. Local postoperative morbidity following preoperative irradiation for locally advanced breast cancer
34. Postmastectomy morbidity after combination preoperative irradiation and chemotherapy for locally advanced breast cancer
35. Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer